(IN BRIEF) The Mercedes-Benz eCitaro G, an all-electric articulated city bus, has been named the Electric Bus Champion of 2024 after excelling in the rigorous comparison test organized by Omnibusspiegel bus magazine in Bonn. This marks the second consecutive victory … Read the full press release
(IN BRIEF) Webuild, along with its US subsidiary Lane, has unveiled a pro bono proposal for the reconstruction of Baltimore’s Francis Scott Key Bridge, which collapsed in March, severing a vital link for the city’s port. The proposal, presented to … Read the full press release
Posted in Business, Construction, Environment, Financial, Government, Industrial, Infrastructure & Utilities, Investment, Italy, Management, News, Security & Safety, Technology
Tagged Baltimore Bridge, Carlo Ratti, Michel Virlogeux, partnership, Pietro Salini, reconstruction, safety, sustainability, Webuild
(IN BRIEF) The Australian Government has granted feasibility licences to Ørsted for its first offshore wind project in Australia, with intentions to grant a licence for a second project pending consultation. These licences provide Ørsted with exclusive site access to … Read the full press release
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated significant progress in treating HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy. The high-level results from the DESTINY-Breast06 Phase … Read the full press release
Posted in Business, Education, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Breast Cancer Patients, Daiichi Sankyo, DESTINY-Breast06, Enhertu, HER2-Low, HER2-Ultralow, Ken Takeshita, partnership, safety, Susan Galbraith
(IN BRIEF) AstraZeneca’s Truqap, in combination with Faslodex, has received a positive recommendation from the European Medicines Agency (EMA) for treating estrogen receptor-positive, HER2‑negative locally advanced or metastatic breast cancer with specific genetic alterations. The recommendation follows promising results from … Read the full press release
(IN BRIEF) Henkel’s adhesive solution, Aquence PS 3017 RE, has been certified by the cyclos-HTP Institute (CHI) for its recyclability, particularly in PET bottle recycling. Designed as a sustainable option, the water-based acrylic pressure sensitive adhesive allows for easy label … Read the full press release
(IN BRIEF) Neste, a leading provider of renewable fuels and sustainable solutions, has honored several contractors globally with the Contractor Safety Award as part of its annual Safety Week, commencing on April 22. The award acknowledges contractors’ outstanding safety commitment … Read the full press release
Posted in Awards, Business, Energy, Gas & Oil, Finland, Industrial, Management, News, Security & Safety
Tagged Award, Contractor Safety Award, Global Contractors, Hannele Jakosuo-Jansson, Neste, safety, Safety Week
(IN BRIEF) GRAHAM has achieved PAS 2080 verification, a globally recognized standard for managing carbon in buildings and infrastructure, showcasing its dedication to integrating carbon considerations throughout its operations. PAS 2080, developed by the British Standards Institution (BSI), offers a … Read the full press release
(IN BRIEF) Pinellas County, Florida, has chosen Kapsch TrafficCom to lead a project aimed at improving mobility and safety with advanced technology solutions, backed by a USD 4.6 million grant from the Federal Highway Administration. With Pinellas County facing significant … Read the full press release
Posted in Austria, Business, Environment, Financial, Government, Industrial, Infrastructure & Utilities, Investment, Management, News, Security & Safety, Technology, Transportation & Logistics
Tagged Dr. Jeff Adler, Kapsch TrafficCom, mobility, partnership, Pinellas County, safety, sustainability, USA
(IN BRIEF) Sanofi’s experimental CD40L antibody, frexalimab, demonstrates encouraging results in a 48-week phase 2 study for relapsing multiple sclerosis (MS). Presented at the American Academy of Neurology Annual Meeting, the data reveals sustained reduction in disease activity and favorable … Read the full press release
Posted in Business, Education, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged CD40L antibody, Erik Wallström, Frexalimab, multiple sclerosis, Patrick Vermersch, safety, Sanofi
(IN BRIEF) Novartis revealed promising data from the ALITHIOS open-label extension study, highlighting the enduring effectiveness of Kesimpta® (ofatumumab) in treating relapsing multiple sclerosis (RMS) over a span of up to six years. The study, presented at the American Academy … Read the full press release
(IN BRIEF) Royal Philips announces the final agreement on a consent decree for its subsidiary, Philips Respironics, with the US Department of Justice (DOJ) and the US Food and Drug Administration (FDA). The decree primarily focuses on Respironics’ US operations, … Read the full press release
Posted in Business, Electronics & Machinery, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Security & Safety, Technology
Tagged DOJ, FDA, Philips, Philips Respironics, Roy Jakobs, safety, Steve C. de Baca
(IN BRIEF) AstraZeneca announces positive outcomes from the ADRIATIC Phase III trial, revealing that its immunotherapy drug Imfinzi (durvalumab) demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS) among patients with limited-stage small cell lung cancer (LS-SCLC) … Read the full press release
(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for ZEVTERA® (ceftobiprole medocaril sodium for injection). The approval covers its use in adult patients with Staphylococcus aureus bloodstream infections (bacteremia), … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Adesh Kaul, Basilea, David Veitch, Dr. Marc Engelhardt, FDA, Pediatric Use, safety, Severe Bacterial Infections, Thomas Holland, Vance G. Fowler, Zevtera®
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acknowledged by the US FDA for treating adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received prior systemic … Read the full press release
Posted in Business, Education, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Biologics License Application (BLA), Breast Cancer Treatment, Daiichi Sankyo, datopotamab deruxtecan, Japan, Ken Takeshita, partnership, safety, Susan Galbraith, sustainability, US FDA
(IN BRIEF) AstraZeneca and Sanofi celebrate the approval of Beyfortus (nirsevimab) in Japan by the Ministry of Health, Labour, and Welfare for preventing lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in neonates, infants, and children entering … Read the full press release
Posted in Business, Environment, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Beyfortus, Dr. Hiroyuki Moriuchi, France, Iskra Reic, Japan, LRTD, partnership, prophylaxis, respiratory syncytial virus, safety, Sanofi, sustainability
(IN BRIEF) AstraZeneca announces the approval of Truqap (capivasertib) in combination with Faslodex (fulvestrant) by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating adult patients with unresectable or recurrent hormone receptor-positive, HER2-negative breast cancer. The approval, based … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Breast Cancer Treatment, Dave Fredrickson, Faslodex, Japan, Masakazu Toi, MHLW, safety, Truqap
(IN BRIEF) Ultomiris (ravulizumab-cwvz) has gained approval from the FDA as the inaugural long-acting C5 complement inhibitor for treating adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). The approval, based on the CHAMPION-NMOSD Phase III trial’s … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AQP4 Ab+, AstraZeneca, Marc Dunoyer, neuromyelitis optica spectrum disorder (NMOSD), safety, Sean J. Pittock, treatment, Ultomiris, USFDA
(IN BRIEF) ZF Group has introduced “ZF LIFETEC” as the new brand identity for its Passive Safety Systems division, reflecting its independent positioning within the ZF Group. With sales of €4.7 billion in 2023, ZF LIFETEC aims to enhance sales … Read the full press release
(IN BRIEF) Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorization for Fabhalta® (iptacopan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?